NDAORALSUSPENSION
Approved
Oct 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
NOXAFIL (posaconazole) by Merck & Co. is [see clinical pharmacology (12. First approved in 2006.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOXAFIL (posaconazole) is an oral azole antifungal suspension approved in 2006 for prevention and treatment of invasive fungal infections in immunocompromised patients. It inhibits fungal cell wall synthesis by blocking lanosterol 14α-demethylase, a key enzyme in ergosterol biosynthesis. The oral suspension formulation enables broad-spectrum coverage against Aspergillus, Candida, and other clinically significant fungi.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30) signals transition from growth to defensive positioning and potential team rightsizing.
Mechanism of Action
[see Clinical Pharmacology (12.4)] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
Started Feb 2022
40 enrolled
Invasive Fungal Infection
Pharmacokinetic of Posaconazole in Critically Ill Patients
Started Feb 2021
10 enrolled
Therapeutic Drug MonitoringCritical Illness
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
Started Jul 2020
31 enrolled
Invasive Aspergillosis
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
Started Mar 2020
249 enrolled
COVID-19 Respiratory InfectionAspergillosis
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
Started Aug 2019
100 enrolled
PosaconazolePharmacokineticsInvasive Candidiases+4 more
Worked on NOXAFIL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.